Alabama settles with Cullman clinic over unapproved semaglutide and tirzepatide

Aurora IV and Wellness, an infusion clinic in Cullman, Alabama, has permanently closed, and its owners have agreed to pay $24,267.50, under a settlement Alabama Attorney General Steve Marshall announced January 12, 2026 ^[1].

The agreement ends a state lawsuit against the clinic and its owners, Amanda and Chris Medders. Of the total, $17,267.50 goes to consumers who submitted complaints to the Attorney General, and $7,000 covers penalties and fees owed to Alabama ^[1]. The Medderses also gave up the right to work in healthcare in any role that involves directly treating patients, and Amanda Medders surrendered her nursing license to the Alabama Board of Nursing ^[1].

Investigators said the clinic advertised its weight-loss injections as "pharmaceutical-grade" when the products were actually research-grade versions of tirzepatide and semaglutide, the two GLP-1 molecules ^[1]. According to the announcement, the manufacturer of the drugs the clinic dispensed expressly labeled them for laboratory research only, meaning they were not approved for human use ^[1]. Tirzepatide is the active ingredient in Mounjaro and Zepbound; semaglutide is the ingredient in Ozempic, Wegovy and Rybelsus.

"Exploiting the need for medical GLP-1 weight-loss medication by using unapproved, research-grade chemicals on unsuspecting patients is an extremely reckless form of consumer deception," Marshall said. He added that "this type of dangerous disregard for patient safety will not be tolerated in Alabama" ^[1].

The settlement follows a temporary restraining order the Attorney General announced in November, after the state sued the business over violations of Alabama's Deceptive Trade Practices Act that it described as serious threats to public health and safety ^[1]. Marshall thanked the Alabama Board of Nursing, the Alabama Board of Medical Examiners and the Cullman Police Department for their help with the investigation and the lawsuit ^[1].

Several details are not spelled out in the announcement. It does not say how many patients received the injections, how many complaints were filed, how many people will divide the damages, or whether anyone was injured. The date the clinic shut down is not given, and there is no description of how or when the damages will reach consumers. Whether federal regulators or other states are examining the same operation has not been disclosed.

Why it matters for patients

People filling a prescription for semaglutide or tirzepatide normally receive an FDA-approved product dispensed by a licensed pharmacy. According to the state's account, what left this clinic's shelves was labeled by its manufacturer as material for laboratory research, a category that is not a medicine and is not reviewed for human use ^[1]. A clinic's advertising can use the same molecule names either way.

Enforcement here came through a state consumer protection law rather than federal drug rules ^[1]. That route let Alabama seek a permanent shutdown, a license surrender and payments to patients. It shows state attorneys general can pursue sellers of unapproved GLP-1 products on their own, running alongside the FDA.

There are limits to what the settlement does. Compensation was set aside for people who contacted the Attorney General's office ^[1]; the announcement names no other way to seek money and describes no effort to reach former patients. The restrictions bind only Aurora IV and Wellness and the Medderses. They say nothing about other clinics or online sellers.

What happens next

The settlement was announced January 12, 2026 ^[1]. The release sets no deadline for the payments and gives no timeline for distributing the damages, so those dates have not been reported. The prior court action in the case began with a temporary restraining order announced in November ^[1].